title: Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.
abstract: The development of new protein subunit vaccines has stimulated the search for improved adjuvants to replace traditional aluminum-containing products. We investigated the adjuvant effects of a synthetic Toll-like receptor 4 (TLR4) agonist on vaccine efficacy in an experimental model of toxic shock syndrome. The TLR4 agonist E6020 has a simplified structure consisting of a hexa-acylated acyclic backbone. The vaccine examined is a recombinantly attenuated form of staphylococcal enterotoxin B (STEBVax). Using cells stably transfected with TLRs, E6020 transduced signals only through TLR4, suggesting monospecificity, while Escherichia coli 055:B5 lipopolysaccharide activated both the TLR2/6 heterodimer and TLR4. Coadministration of E6020 with STEBVax, by the intramuscular or intranasal route, induced significant levels of immunoglobulin G (IgG) in BALB/c mice. Further, increased IgG production resulted from the combination of E6020 with aluminum hydroxide adjuvant (AH). The antibody response to the vaccine coadministered with E6020 was a mixed Th1/Th2 response, as opposed to the Th2-biased response obtained with AH. Mice vaccinated with STEBVax coadministered with AH, TLR4 agonists, or a combination of both adjuvants were protected from toxic shock. Our data demonstrate the effectiveness of the synthetic TLR4 agonist E6020 as an alternative adjuvant for protein subunit vaccines that may also be used in combination with traditional aluminum-containing adjuvants.
authors: Laboratory of Molecular Immunology, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA. ulrich@ncifcrf.gov
authors: Garry L
authors: GL
authors: Morefield
authors: Lynn D
authors: LD
authors: Hawkins
authors: Sally T
authors: ST
authors: Ishizaka
authors: Teri L
authors: TL
authors: Kissner
authors: Robert G
authors: RG
authors: Ulrich
mesh_terms: D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide / Q000276:immunology / Q000494:pharmacology; D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D004768:Enterotoxins / Q000276:immunology*; D007136:Immunoglobulins / Q000097:blood; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D012772:Shock, Septic / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D015398:Signal Transduction; D013211:Staphylococcus aureus / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000276:immunology; D051197:Toll-Like Receptor 4 / Q000819:agonists* / Q000276:immunology; D051216:Toll-Like Receptor 6 / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D016207:Cytokines; D004768:Enterotoxins; D007136:Immunoglobulins; D008070:Lipopolysaccharides; C493487:Tlr4 protein, mouse; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051216:Toll-Like Receptor 6; C031818:enterotoxin B, staphylococcal; D000536:Aluminum Hydroxide
references: Mol Med Today. 2000 Mar;6(3):125-32
references: 10689316
references: Mol Syst Biol. 2006;2:2006.0015
references: 16738560
references: J Immunol. 2000 Jul 15;165(2):618-22
references: 10878331
references: Trends Microbiol. 2000 Oct;8(10):452-6
references: 11044679
references: J Immunol. 2001 Jan 1;166(1):249-55
references: 11123299
references: Cell Signal. 2001 Feb;13(2):85-94
references: 11257452
references: Vaccine. 2001 Oct 12;20(1-2):59-66
references: 11567746
references: Infect Immun. 2002 Feb;70(2):692-701
references: 11796601
references: J Pharmacol Exp Ther. 2002 Feb;300(2):655-61
references: 11805229
references: Scand J Immunol. 2002 Mar;55(3):293-303
references: 11940236
references: Vaccine. 2003 Feb 14;21(9-10):961-70
references: 12547609
references: Curr Mol Med. 2003 Jun;3(4):373-85
references: 12776992
references: Eur J Immunol. 2003 Jul;33(7):1767-75
references: 12811836
references: Clin Immunol. 2003 Jul;108(1):51-9
references: 12865071
references: Nat Immunol. 2004 Oct;5(10):987-95
references: 15454922
references: Johns Hopkins Med J. 1969 Jun;124(6):291-5
references: 4895520
references: Nat Struct Biol. 1995 Jul;2(7):554-60
references: 7664123
references: Trends Microbiol. 1995 Dec;3(12):463-8
references: 8800837
references: Dev Biol Stand. 1996;87:113-24
references: 8854008
references: Curr Opin Immunol. 1997 Feb;9(1):4-9
references: 9039775
references: Vaccine. 1998 Nov;16(19):1857-64
references: 9795392
references: Science. 1998 Dec 11;282(5396):2085-8
references: 9851930
references: J Biol Chem. 1999 Apr 16;274(16):10689-92
references: 10196138
references: Vaccine. 2006 Mar 6;24(10):1665-9
references: 16246468
references: J Immunol. 2000 Jun 1;164(11):5998-6004
references: 10820283